|
Aug 26
|
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
|
|
Apr 29
|
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
|
|
Dec 22
|
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%
|
|
Dec 10
|
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
|
|
Jul 13
|
Owning 32% shares,hedge funds owners seem interested in Molecular Partners AG (VTX:MOLN),
|